跳至主要内容
临床试验/NCT00098124
NCT00098124已完成3 期

A Phase III Pivotal, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Milnacipran for the Treatment of Fibromyalgia

Forest Laboratories81 个研究点 分布在 1 个国家目标入组 1,200 人开始时间: 2004年11月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
1,200
试验地点
81
主要终点
Composite responder analysis based on pain and patient global status, with or without physical function.

研究概览

简要总结

Antidepressants of all varieties represent a common form of therapy for many chronic states including fibromyalgia. The majority of antidepressants increase the levels of serotonin or norepinephrine in the central nervous system. Milnacipran is a dual norepinephrine and serotonin reuptake inhibitor and may be effective in the treatment of fibromyalgia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) Criteria

排除标准

  • Psychiatric illness
  • Depression
  • Suicidal risk
  • Substance abuse
  • Pulmonary dysfunction
  • Renal impairment
  • Active cardiac disease
  • Liver disease
  • Autoimmune disease
  • Sleep apnea
  • Inflammatory bowel disease

结局指标

主要结局

Composite responder analysis based on pain and patient global status, with or without physical function.

次要结局

  • Quality of Life
  • Health Assessment Questionnaire (HAQ) Disability Index
  • Fatigue, sleep and cognitive assessments

研究者

发起方
Forest Laboratories
申办方类型
Industry

研究点 (81)

Loading locations...

相似试验